期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

OPG/RANKL/RANK系统及其临床应用 被引量：11

OPG/RANKL/RANK and their clinical application
暂未订购
导出
摘要 人OPG,RANK和RANKL是3个肿瘤坏死因子家族新成员,主要存在于人的骨髓及其他少数组织中。2000年美国骨与矿物质研究协会对其给予了标准化命名,并统称为OPG/RANKL/RANK系统。作为破骨细胞形成、分化和骨吸收调节的关键调节物,OPG/RANKL/RANK系统在骨质疏松、骨硬化病、类风湿性关节炎、骨肿瘤、Paget’s病、牙周炎及正畸牙移动等临床疾病的发病机制及治疗方面均取得了较大进展。 Human osteoprotegrin （OPG）, human receptor activator of NF-κB （RANK） and human receptor activator of NF-κB ligand （RANKL） are three new members of the tumor necrosis factor （TNF） receptor superfamily found in 1997 and 1998. They mainly exist in human bone marrow and other few tissues. But then, people could not know them very well and gave them unequal names, thus, in 2000, ASBMR made them names normalization and called them OPG/RANKL/RANK. As critical molecular determinants of osteoclastogenesis and regulators of bone resorption, OPG/RANKL/RANK has revolutionized our understanding of the processes of normal and pathological bone metabolism. By now, great progress has been made in osteoporosis, bone sclerosis, rheumatoid arthritis, bone tumor, Paget＇ s disease,periodontitis and orthodontic tooth movement.
作者 刘长庚 凌天牖 黄生高
机构地区 益阳医学高等专科学校口腔中心 中南大学湘雅二医院口腔科
出处 《国际病理科学与临床杂志》 CAS 2007年第6期534-538,共5页 Journal of International Pathology and Clinical Medicine
基金 湖南省卫生厅科研基金(B2007195)~~
关键词 骨保护素 核因子ΚB受体活化因子配体 核因子ΚB受体活化因子 osteoprotegrin （OPG） receptor activator of NF-κB （RANK） receptor activator of NF-κB ligand （RANKL）
分类号 R68 [医药卫生—骨科学]
  • 相关文献

参考文献29

  • 1Krieger I, Odrowaz-syoniewska G. Osteoprotegerin[ J]. Ortop Traumatol Rehabil,200d. ,6 (1 ) : 123-129.
  • 2Suda T,Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families[ J]. Endocrine Rcv, 1999,20 (3) :345-357.
  • 3Kiechl S, Werner P, Knoflach M,et al. The osteoprotegerin/RANK/ RANKL system: a bone key to vascular disease[ J ]. Expert Rev Cardiovasc Ther, 2006, 4(6):801-811.
  • 4Blair J M, Zheng Y, Dunstan C R. RANK ligand[J], lnt J Biothem Cell Biol, 2007,39(6) :1077-1081.
  • 5The American Society for Bone and Mineral President' s Committee on Nomenclature. Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption[J]. Bone,2000,27 ( 1 ) :761.
  • 6Sasaki N,Kusano E, Bone and bone related biochemical examinations. Bone and collagen related metabolites, Measurement and clinical role of OPG[ J ]. Clin Calcium ,2006,16 (6) :956-962.
  • 7Asuda H. Bone and bone related biochemical examinations. Bone and collagen related metabolites. Receptor acrid'attar of NF-kappaB ligand (RANKL) [ J ]. Clin Calcium ,2006,16 (6) :964-970.
  • 8Zhang Y H, Heulsmann A, Tondravi M M, et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type I receptor and RANK signaling pathways [J]. JBiolChem, 2001,276(1):563-568.
  • 9Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclastogenesis and bone disease[ J ]. Trends Mol Med, 2006,12(1 ) :17-25.
  • 10Yang X, Halladay D, Onyia J E, et at. Protein Kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast like cells [ J ]. Biochem Biophis Res Commun, 2002,290 ( 1 ) : 42- 46.

二级参考文献12

  • 1Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappa B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis[ J ]. Arthritis Rheum,2000,43(2) :259 - 269.
  • 2Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclast inhibitory factor and is identical to TRANCE/RANKL[J]. Proc Natl Acad Sci USA, 1998,95(7) :3597 - 3602.
  • 3Quinn JMW, Horwood NJ, Elliott J, et al. Fibroblastic stromal cells express receptor activator of NF-kappa Bligand and support osteoelast differentiation[ J] .J Bone Miner Res,2000,15(8):1459- 1466.
  • 4LorenzC, Hotbauer, ArminE, etal. Role of receptor activator of NF kB ligand factor and osteoprotegerin in bone biology [ J ]. J Mol Med,2001,79(5 - 6) :243 - 253.
  • 5Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation[ J ]. Cell,1998,93(2): 165 - 176.
  • 6Yasuda H, Shima N, Nakagawa N, et al. Ideatity of osteoclastogenesis inhibitory factor(OCIF) and osteoprotegerin(OPG): a mechanism by which OPG/OCIF inhibits osteoclasttogenesis in vitro[J]. Endocrinology, 1998,139(3): 1329 - 1337.
  • 7Al Haj A, Lafont A, Durand E, et al. Effect of adenovirus-mediated overexpression of decorin on metalloproteinases, tissue inhibitors of metalloproteinases and cytokines secretion by human gingival fibroblasts [J]. Matrix Biol,2003,22(3) :251 - 258.
  • 8Hofbauer LC, Lacey DL, Dunstan CR, et al. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells[ J ]. Bone, 1999, 25 ( 3 ):255 - 259.
  • 9Kraan MC, Haringman JJ, Ahern MJ, et al. Quantification of the cell infiltrate in synovial tissue by digital image analysis[J]. Rheumatology,2000,39( 1 ) :43 - 49.
  • 10Tak PP, Van Der, Lubbe PA, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis[ J]. Arthritis Rheum, 1995,38(10): 1457 - 1465.

共引文献15

同被引文献155

引证文献11

二级引证文献53

国际病理科学与临床杂志
2007年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部